Search

Background Apelin is an endogenous neuropeptide that binds to the G-protein-coupled receptor (APJ) and participates in a variety of physiological processes in the heart, lungs and other peripheral organs. Intriguingly, [Pyr1]-Apelin-13, a highly potent pyroglutamic form of apelin, has the potential to bind to and be degraded by angiotensin-converting enzyme 2 (ACE2). ACE2 is known to operate as a viral receptor in the early stages of severe acute respiratory coronavirus (SARS-CoV-2) infection. Aim This study aimed to determine if apelin protects against SARS-CoV-2 infection by inhibiting ACE2 binding to SARS-CoV-2 spike protein. Design and methods To determine whether [Pyr1]-Apelin-13 inhibits ACE2 binding to the SARS-CoV-2 spike protein (S protein), we performed a cell-to-cell fusion assay using ACE2-expressing cells and S protein-expressing cells and a pseudovirus-based inhibition assay. We then analyzed publicly available transcriptome data while focusing on the beneficial effects of apelin on the lungs. Results We found that [Pyr1]-Apelin-13 inhibits cell-to-cell fusion mediated by ACE2 binding to the S protein. In this experiment, [Pyr1]-Apelin-13 protected human bronchial epithelial cells, infected with pseudo-typed lentivirus-producing S protein, against viral infection. In the presence of [Pyr1]-Apelin-13, the level of viral spike protein expression was also reduced in a concentration-dependent manner. Transcriptome analysis revealed that apelin may control inflammatory responses to viral infection by inhibiting the nuclear factor kappa B pathway. Conclusion Apelin is a potential therapeutic candidate against SARS-CoV-2 infection.

Background Red ginseng contains components, including microelements, vitamins, essential oils, and fatty acids, that can be used in skincare to delay the aging process. We investigated the effects of red ginseng treatment on skin elasticity by assessing cellular stiffness and measuring collagen protein synthesis. Methods Human dermal fibroblasts were treated with red ginseng, and the resulting changes in stiffness were investigated using atomic force microscopy. Cytoskeletal changes and mRNA expression of biomarkers of aging, including that of procollagens I and VII, elastin, and fibrillin-1, were investigated. Collagen in a human skin equivalent treated with red ginseng was visualized via hematoxylin and eosin staining, scanning electron microscopy, and atomic force microscopy. Results and conclusion The stiffness of fibroblasts was significantly reduced by treatment with red ginseng concentrations of ≥ 0.8 mg/mL. The ratio of F-actin to G-actin decreased after treatment, which corresponded to a change in fibroblast stiffness. The storage modulus (G′) and loss modulus (G″) of the skin equivalent were both lowered by red ginseng treatment. This result indicates that the viscoelasticity of the skin equivalent can be restored by red ginseng treatment.

OBJECTIVES: This study compared the results of meta-analysis with and without adjustment for the healthy worker effect on the association between working in the semiconductor industry and cancer mortality.METHODS: Six studies that reported standardized mortality ratios (SMRs) for cancers were selected for meta-analysis. Using a random-effects model, the SMR results from each study were combined for all cancers and leukemias to estimate the summary SMRs (95% confidence interval, CI). To adjust for the healthy worker effect, the relative standardized mortality ratio (rSMR=SMRx/SMRnot x) were calculated using observed and expected counts for the specific cause of interest (i.e., all cancers and leukemias) and the observed and expected counts for all other causes of mortality. Then, the rSMR results were combined to estimate the summary rSMRs (95% CIs).RESULTS: The SMRs for all causes of mortality among semiconductor industry workers ranged from 0.25 to 0.80, which reflects a significant healthy worker effect. A remarkable difference was found between the summary SMRs and the summary rSMRs. The summary SMR for all cancers was 0.70 (95% CI, 0.63 to 0.79) whereas the summary rSMR was 1.38 (95% CI, 1.20 to 1.59). The summary SMR for leukemia was 0.88 (95% CI, 0.72 to 1.07), and the summary rSMR was 1.88 (95% CI, 1.20 to 2.95).CONCLUSIONS: Our results suggest that adjustment for the healthy worker effect (i.e., rSMR) may be useful in meta-analyses of cohort studies reporting SMRs.

In recent years, safety issues surrounding robots have increased in importance, as more robots are in close contact with humans, both in industrial fields and elsewhere. Safety standards for industrial robots operating in specific spaces have been established, but no such standards have been specified for collaborative and service robots. To establish safety standards for such robots, we assessed pressure pain thresholds for collisions between humans and robots, under the assumption that the pain threshold is lower than the mild injury threshold. The pressure pain threshold for collision with a robot was measured in 90 male Korean adults using a homemade collision system. The pain thresholds were measured three times at 15 sites, including the forehead. The highest threshold was 196.1 ± 85.8 N/cm2 at the back of the hand, and the lowest was 65.1 ± 22.6 N/cm2 at an arm nerve. Moderate thresholds, i.e., 100–120 N/cm2, were noted on the forehead, neck muscle, ball of the thumb, and shin. The thresholds of participants < 30 years of age were lower, by 3–33%, than those of participants aged > 30 years. Thresholds differed by body mass index only at certain sites, including the shoulder joint, neck, and back of the hand. The pressure pain threshold depended on individual characteristics, body site, and age. The threshold relevant to potential human-robot collisions was determined to be between 65.1 ± 22.6 and 196.1 ± 85.8 N/cm2.

Objectives: The purpose of this study was to assess excavator drivers in order to determine the proportion showing subjective symptoms of musculoskeletal disorders and to evaluate the association between the symptoms and characteristics of the subjects. Methods: A questionnaire survey was conducted to collect the information on participants’ age, average working hours per day, duration of career (years), work-related musculoskeletal symptoms, and more. The final dataset included 141 excavator drivers. Frequency and percentage were summarized and then the associations between the characteristics of the subjects and symptoms were evaluated as odds ratios (ORs) and 95% confidence intervals (CIs) using multiple logistic regression analysis. Results: Seventy-six percent of the currently reported musculoskeletal symptoms. Those who have musculoskeletal symptoms attributed their symptoms to unstable posture at work, mental stress or vibrations. There was a significant association between symptoms of musculoskeletal disorders and career of excavator drivers (P for trend=0.04). Conclusions: The results of this study suggest that the prevalence of musculoskeletal disorders may be high among excavator drivers and warrants well-designed studies on work-related disorders among excavator drivers.

In general, the storage life of hardy kiwifruit (Actinidia arguta ) is approximately one month, even in cold storage, which is a limiting factor for its commercialization due to the short marketing period. This short shelf life is in contrast to those of green kiwifruit (A. deliciosa , 6 to 8 months) and gold kiwifruit (A. chinensis , 4 to 6 months). To increase the storage life of hardy kiwifruit, we performed a cross between A. arguta (a local collection, ‘Hy2-1’, female) and A. deliciosa (‘Matua’, male) at Wando station at the Fruit Research Institute of JARES, Korea in 1999. After the first selection in 2006, we clonally propagated the hybrid plants by grafting them onto A. arguta seedlings in Gwangyang and Haenam province, Korea. We performed the final selection of this cultivar in 2012 and applied for plant protection rights from the Korea Forest Research Institute in 2013. Several experimental orchards have been established for commercial production. ‘Mansu’ begins to flower on May 20 in Gwangyang. The horticultural maturity date in ‘Mansu’, when the soluble solid content reaches 7°Bx, is October 15, whereas that of the control variety (‘Chiak’) is October 5. The average fruit size of ‘Mansu’ is approximately 15 g. The soluble solid content of ‘Mansu’ is approximately 16 to 17°Bx after ripening. The total yield of mature ‘Mansu’ vines is estimated to be 2.2 to 2.5 tons per 10a. The fruit firmness of ‘Mansu’ exceeded 1.5 ㎏/5 ㎜O until 70 days after storage (at 0 and 1℃). Therefore, ‘Mansu’ fruits have much longer storability than the control. The cultivation and production of ‘Mansu’ may extend the marketing period for hardy kiwifruit.